RD Saúde (B3: RADL3) financial statements
The consolidated income statement, balance sheet and cash flow statement of RD Saúde for its last 10 fiscal years, as filed with the regulator, in millions of Brazilian reais. At the end of fiscal 2025 it had BRL 25,170m in total assets and BRL 7,322m in equity.
Income statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | BRL 44,250m | BRL 38,872m | BRL 33,974m | BRL 29,067m | BRL 24,127m | BRL 20,067m | BRL 17,566m | BRL 14,801m | BRL 13,213m | BRL 11,257m |
| Cost of sales | BRL 31,286m | BRL 27,315m | BRL 23,766m | BRL 20,258m | BRL 16,921m | BRL 14,176m | BRL 12,367m | BRL 10,356m | BRL 9,225m | BRL 7,752m |
| Gross profit | BRL 12,965m | BRL 11,557m | BRL 10,207m | BRL 8,809m | BRL 7,206m | BRL 5,891m | BRL 5,198m | BRL 4,446m | BRL 3,988m | BRL 3,504m |
| Operating profit | BRL 2,744m | BRL 2,352m | BRL 2,080m | BRL 1,839m | BRL 1,366m | BRL 916.0m | BRL 1,118m | BRL 721.5m | BRL 792.6m | BRL 705.5m |
| Profit before tax | BRL 1,448m | BRL 1,419m | BRL 1,217m | BRL 1,193m | BRL 987.3m | BRL 616.4m | BRL 784.2m | BRL 638.9m | BRL 686.5m | BRL 595.2m |
| Income tax | BRL 147.8m | BRL 207.6m | BRL 129.6m | BRL 178.2m | BRL 223.1m | BRL 120.8m | −BRL 4.6m | BRL 129.5m | BRL 173.9m | BRL 144.0m |
| Net profit | BRL 1,297m | BRL 1,200m | BRL 1,055m | BRL 996.1m | BRL 751.9m | BRL 484.4m | BRL 772.2m | BRL 502.4m | BRL 511.2m | BRL 447.7m |
Balance sheet
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | BRL 25,170m | BRL 22,164m | BRL 20,094m | BRL 17,185m | BRL 14,776m | BRL 13,828m | BRL 12,248m | BRL 7,352m | BRL 6,464m | BRL 5,659m |
| Current assets | BRL 14,904m | BRL 12,704m | BRL 11,562m | BRL 9,577m | BRL 7,719m | BRL 7,020m | BRL 5,756m | BRL 4,530m | BRL 3,928m | BRL 3,428m |
| Cash | BRL 509.6m | BRL 528.0m | BRL 412.3m | BRL 433.5m | BRL 356.1m | BRL 880.4m | BRL 299.2m | BRL 241.6m | BRL 264.9m | BRL 276.6m |
| Total liabilities | BRL 17,835m | BRL 15,717m | BRL 14,066m | BRL 11,782m | BRL 10,057m | BRL 9,402m | BRL 8,172m | BRL 3,817m | BRL 3,214m | BRL 2,723m |
| Current liabilities | BRL 10,194m | BRL 9,195m | BRL 8,079m | BRL 6,367m | BRL 5,896m | BRL 4,801m | BRL 4,078m | BRL 2,913m | BRL 2,494m | BRL 2,185m |
| Equity | BRL 7,322m | BRL 6,433m | BRL 5,956m | BRL 5,341m | BRL 4,678m | BRL 4,363m | BRL 4,025m | BRL 3,500m | BRL 3,223m | BRL 2,910m |
| Equity including minorities | BRL 7,336m | BRL 6,447m | BRL 6,028m | BRL 5,403m | BRL 4,719m | BRL 4,426m | BRL 4,076m | BRL 3,535m | BRL 3,250m | BRL 2,936m |
| Minority interests | BRL 13.8m | BRL 13.4m | BRL 72.3m | BRL 62.1m | BRL 41.1m | BRL 62.5m | BRL 51.4m | BRL 34.9m | BRL 27.9m | BRL 26.2m |
Cash flow statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | BRL 2,431m | BRL 2,771m | BRL 1,785m | BRL 1,682m | BRL 1,551m | BRL 1,477m | BRL 749.1m | BRL 682.9m | BRL 628.8m | BRL 555.5m |
| Investing cash flow | −BRL 1,406m | −BRL 1,413m | −BRL 1,307m | −BRL 1,230m | −BRL 886.0m | −BRL 673.1m | −BRL 2.7m | −BRL 703.0m | −BRL 639.2m | −BRL 489.1m |
| Financing cash flow | −BRL 1,043m | −BRL 1,243m | −BRL 499.4m | −BRL 375.3m | −BRL 1,189m | −BRL 223.0m | −BRL 688.7m | −BRL 3.2m | −BRL 1.4m | −BRL 55.9m |
| Dividends paid | −BRL 652.8m | −BRL 474.6m | −BRL 465.9m | −BRL 324.1m | −BRL 265.0m | −BRL 190.5m | −BRL 186.6m | −BRL 173.6m | −BRL 170.8m | −BRL 153.3m |
Where each figure comes from
From the annual financial statements (DFP) that RD Saúde files with the CVM, the Brazilian securities regulator. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. If an item is not tagged in the filing, it is not in the table. The summary of the last fiscal year is on the RD Saúde page.
More companies from Brazil and the rest of the region: Latin American stocks.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.